Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289509 | 1.00 | HSD17B10 (0.43) | HSD17B10CASP3CNR1CNR2DAGLA | |
| SCHEMBL18626075 | 1.00 | HSD17B10 (0.43) | HSD17B10CASP3CNR1CNR2DAGLA | |
| SCHEMBL6646539 | 0.95 | HSD17B10 (0.39) | HSD17B10CASP3CNR1CNR2DAGLA | |
| SCHEMBL4560121 | 0.81 | HSD17B10 (0.36) | HSD17B10CASP3HRH3HPGDROCK2 | |
| SCHEMBL6377618 | 0.81 | POLB (0.45) | CNR1CNR2DAGLASMN1; SMN2 | |
| SCHEMBL555493 | 0.81 | POLB (0.45) | CNR1CNR2DAGLASMN1; SMN2 | |
| SCHEMBL14113486 | 0.81 | POLB (0.45) | CNR1CNR2DAGLASMN1; SMN2 | |
| SCHEMBL14938657 | 0.77 | CASP3 (0.43) | HSD17B10CASP3HRH3HPGDROCK2 | |
| SCHEMBL14366142 | 0.77 | CNR1 (0.37) | CNR1CNR2DAGLAMEN1KMT2A | |
| SCHEMBL8490471 | 0.77 | HSD17B10 (0.42) | HSD17B10CASP3HRH3HPGDROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | NIPRI LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| EP-1086941-B1 | PROCESS FOR PREPARING REDUCTANTS OF UNSATURATED ORGANIC COMPOUNDS BY THE USE OF TRICHLOROSILANE AND REDUCING AGENTS | TOKUYAMA CORP (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-6420613-B1 | CHEMICAL REDUCTION WITH TRICHLOROSILANE | TOKUYAMA CORPORATION (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1086941-A1 | PROCESS FOR PREPARING REDUCTANTS OF UNSATURATED ORGANIC COMPOUNDS BY THE USE OF TRICHLOROSILANE AND REDUCING AGENTS | TOKUYAMA CORPORATION (JP) | 2001-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047221-A1 | COMPOUNDS AND COMPOSITIONS USEFUL IN THE TREATMENT OF NEOPLASIA | MKI67, TP53, CCNA1 | HSD17B10 804/4885CASP3 316/4885CNR1 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.